Join to access to all OVN content. Join for Free
Aspiring MSL Insight: What Types of MSL Presentations are Acceptable in a Final Interview?

Aspiring MSL Insight: What Types of MSL Presentations are Acceptable in a Final Interview?


Share This Article


Aspiring MSL Insight: What Types of MSL Presentations are Acceptable in a Final Interview? 🧑‍⚕️🎤

If you’re an Aspiring MSL, you likely realize how important the MSL presentation is during the final interview. But you may be wondering, “What type of presentation should I do? 🤔"

So, for this Aspiring MSL Insight, Michael Pietrack describes the top three types of MSL presentations that are acceptable in a final interview.

1️⃣ The most common type of presentation used in MSL interviews is the clinical data presentation. 📊 This is a good style to showcase your ability to understand and communicate scientific data effectively. If this is the route you take, choose a recent, relevant study and provide a comprehensive overview, including the study design, methodology, results, and implications. So, the most common type is a clinical data presentation.

2️⃣ The second most common presentation type is a therapy overview presentation. 💊 This type of presentation will showcase your knowledge of the therapeutic area and the company’s products, because you’ll be providing an in-depth overview of a particular drug’s mechanism of action or how that drug fits into the current treatment landscape. So, the second type is a therapy overview.

3️⃣ The third most common type of presentation given at a final interview for an MSL job is a journal club style presentation. 📚 In the pharmaceutical industry, a jour nal club is a formal meeting where individuals (typically healthcare professionals, researchers, or members of a pharmaceutical company) gather to critically evaluate and discuss recent articles from scientific journals. If you go this route, choose a recent and relevant article from a highly-respected journal that addresses a significant question or an advancement in the field.

Subscribe to the channel

Follow Michael Pietrack on LinkedIn

Join our private LinkedIn Job Board: "KBIC Jobs - Medical Affairs"

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Podcast
Patient Education for Next-Generation Sequencing to Guide Cancer Therapy
OVN Avatar The Oncology Nursing Podcast

Patient Education for Next-Generation Sequencing to Guide Cancer Therapy

Article
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
OVN Avatar Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD

Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved

Explore OVN